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Tuberous sclerosis complex (TSC) is a tumor suppressor gene syndrome in which severe renal cystic disease
can occur. Many renal cystic diseases, including autosomal dominant polycystic kidney disease (ADPKD), are
associated with absence or dysfunction of the primary cilium. We report here that hamartin (TSC1) localizes to
the basal body of the primary cilium, and that Tsc1
2/2 and Tsc2
2/2 mouse embryonic ﬁbroblasts (MEFs) are
signiﬁcantly more likely to contain a primary cilium than wild-type controls. In addition, the cilia of Tsc1
2/2
and Tsc2
2/2 MEFs are 17–27% longer than cilia from wild-type MEFs. These data suggest a novel type of cili-
ary disruption in TSC, associated with enhanced cilia development. The TSC1 and TSC2 proteins function as a
heterodimer to inhibit the activity of the mammalian target of rapamycin complex 1 (TORC1). The enhanced
ciliary formation in the Tsc1
2/2 and Tsc2
2/2 MEFs was not abrogated by rapamycin, which indicates a
TORC1-independent mechanism. Polycystin 1 (PC1), the product of the PKD1 gene, has been found to interact
with TSC2, but Pkd1
2/2 MEFs did not have enhanced ciliary formation. Furthermore, while activation of mTOR
has been observed in renal cysts from ADPKD patients, Pkd1
2/2 MEFs did not have evidence of constitutive
mTOR activation, thereby underscoring the independent functions of the TSC proteins and PC1 in regulation
of primary cilia and mTOR. Our data link the TSC proteins with the primary cilium and reveal a novel pheno-
type of enhanced ciliary formation in a cyst-associated disease.
INTRODUCTION
Tuberous sclerosis complex (TSC) is a tumor suppressor gene
syndrome (1) associated with renal cystic disease (2–7). TSC
patients can also develop seizures, mental retardation, autism
and tumors in the brain, retina, kidney, heart and skin (8). In
a study of 224 TSC patients (74% of whom were under the
age of 15), the incidence of renal cysts was 16% in patients
with germline TSC1 mutations and 25% in patients with germ-
line TSC2 mutations (9). The protein products of the TSC1 and
TSC2 genes, hamartin and tuberin, respectively, physically
interact (10,11) and function as a heterodimeric complex to
inhibit the mammalian target of rapamycin complex 1
(mTORC1) (12–17). mTORC1 contains mTOR, GbL and
Raptor, and controls protein synthesis and cell growth by inte-
grating mitogenic signals and nutrient availability with protein
synthesis, via substrates including p70 S6 Kinase (S6K) (18–
22). Tuberin inhibits mTORC1 via the Ras homologue Rheb,
which is a key target of tuberin’s highly conserved GTPase
activating protein domain (23–28).
Autosomal dominant polycystic kidney disease (ADPKD) is
one of the most common hereditary disorders in humans, with
a prevalence of about 1:1000 (29). Eighty-ﬁve percent of
ADPKD is caused by germline mutations in the chromosome
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protein, with most of the remaining cases caused by mutations
in the chromosome 4q PKD2 gene, which encodes for poly-
cystin 2 (PC2). Cyst number and size increase with age, even-
tually numbering in the hundreds or thousands, often leading
to dialysis-dependent end-stage renal disease (29). Extra-renal
manifestations of ADPKD include cysts in the liver and
pancreas, mitral valve prolapse and intracranial and aortic
aneurysms (29–31).
TSC2 and PKD1 are adjacent genes on chromosome
16p13.3, separated by fewer than 100 base pairs. Adults
with TSC marked by severe renal cystic disease tend to have
large TSC2 deletions, some of which extend into the 30 end
of PKD1 (2). Contiguous germline deletion of the TSC2 and
PKD1 genes is associated with severe infantile-onset polycys-
tic kidney disease (2,3,32,33). It was recently reported that
tuberin co-immunoprecipitates with the C-terminal cyto-
plasmic domain of PC1, and that cysts from patients with
ADPKD have evidence of mTOR pathway activation (34),
leading to the hypothesis that PC1 inhibits the mTOR
pathway via a direct interaction with TSC2 (35–37).
Many proteins associated with renal cystic disease, includ-
ing PC1, have been linked with the function of the primary
cilium (38–40). It is hypothesized that ciliary-mediated sen-
sation of the environment outside of the cell maintains a
growth-arrested phenotype in mature tubules and that loss of
ciliary-mediated sensation leads to dysregulated growth
(reviewed in 41–50). Proteins associated with ADPKD
(PC1, PC2), autosomal recessive PKD (ﬁbrocystin, polaris,
cystin, inversion), nephronophthisis (nephrocystin, inversion),
oro-facio-digital syndrome (OFD1) and Bardet–Biedl syn-
drome (BBS proteins 1, 4, 5 and 8) localize to the shaft of
the primary cilium, the basal body and/or the centrosome
(38,39,42,51–53). The von Hippel-Lindau (VHL) tumor sup-
pressor protein, which is associated with renal cell carcinoma,
has also recently been found to localize to the cilium (54,55)
and to regulate cilia formation and maintenance (54–56).
Mutations in some cyst-associated proteins, including PC1
and PC2, cause defects in the function of the primary cilium
(38,46). Mutations in other proteins, including polaris,
KIF3A and VHL, lead to shortening or complete loss of the
cilium (40,55,57–59), while mutations in the proteins Bbs4
and Nek8 lead to longer cilia (60,61).
The centrosome, composed of two centrioles, serves as the
microtubule-organizing center of the cell and regulates cell
division, migration and polarity (41). In cells with a primary
cilium, the mother centriole of the centrosome serves as the
basal body and nucleates cilia development. Several
cyst-associated proteins localize to the basal body of the
cilium, including BBS-8 (62), nephrocystin-4 (52) and
polaris (51). In previous work, we found that endogenous
hamartin localizes to the centrosome (63). Here we show
that hamartin (TSC1) localizes to the basal body of the
primary cilium, and that Tsc1
2/2 and Tsc2
2/2 mouse
embryonic ﬁbroblasts (MEFs) have a higher fraction of
ciliated cells than control MEFs. In addition, the cilia of
Tsc1
2/2 and Tsc2
2/2 MEFs are 17–27% longer than wild-
type MEF cilia. This enhanced cilia development was not
abrogated by rapamycin, and Pkd1
2/2 MEFs did not have
enhanced ciliary formation, indicating that the phenotype
is rapamycin-insensitive and PC1-independent. Despite the
previously observed links between Pkd1 and mTOR, we
observe hyperphosphorylation of S6 in only a subset (30–
35%) of ADPKD cysts, while the remaining 65–70% have
low levels of mTOR activation, suggesting that additional
mechanisms are required to fully activate mTOR in human
ADPKD or that mTOR is active primarily in early stage
disease. In addition, no evidence of mTOR activation was
observed in Pkd1-null MEFs. Together, these data link the
TSC proteins with the primary cilium, suggest a novel para-
digm of ciliary signaling disruption in TSC associated with
enhanced cilia development, and highlight the independent
functions of TSC2 and PC1 in regulation of the primary
cilium and mTOR.
RESULTS
Hamartin (TSC1) is localized to the basal body
We previously reported that TSC1 localizes to the centrosome
in Cos7 and HeLa cells (63). Because the centrosome gives
rise to the basal body of the primary cilium, we hypothesized
that hamartin is basal body localized. Human retinal pigmen-
ted epithelial cells (RPE1) were serum starved for 48 h to
induce cilia growth, ﬁxed, and co-stained with anti-a-acetyl-
ated tubulin antibody to identify cilia, anti-g-tubulin antibody
to identify centrosomes, and anti-hamartin antibody. Endogen-
ous hamartin localized to cytoplasmic vesicular structures as
previously reported (10,11) and also to the centrosome in
RPE1 cells (arrowheads, Fig. 1A). In cells with a primary
cilium, hamartin is localized in the basal body at the base of
the cilia (arrows, Fig. 1B). Hamartin also localized to the
basal body in a human kidney epithelial cell line, HK-2
(Fig. 1C). To verify the speciﬁcity of the hamartin antibody,
Tsc1-null MEFs (Tsc1
2/2/vector) and Tsc1
2/2 MEFs with
re-introduced TSC1 (Tsc1
2/2/TSC1) were co-stained with
anti-g-tubulin antibody to identify centrosomes,
anti-a-acetylated tubulin antibody to identify cilia, and anti-
hamartin antibody. Hamartin colocalized with the centrosome
and basal body in the Tsc1
2/2/TSC1 cells, and not in the
Tsc1
2/2/vector cells (Supplementary Material, Fig. S1A–D).
Loss of hamartin (Tsc1) enhances ciliary formation
The primary cilium is formed and resorbed in connection with
the cell cycle, with cilia formation directly after mitosis and
cilia disassembly either at cell cycle entry after G0 or prior to
mitotic entry, depending on the cell type (64,65). To determine
whetherTSC1 regulates ciliary formation,cilia wereinduced in
Tsc1
2/2 andTsc1
þ/þ MEFsbyculturingthecells for48 hafter
reaching cell contact-induced growth arrest (referred to in sub-
sequent experiments as conﬂuency-induced ciliary formation).
Cells were then ﬁxed, probed with antibodies to a-acetylated
tubulin (to identify cilia) and g-tubulin (to identify centro-
somes) and scored for cilia by an observer blinded to the
experimental conditions. We found that 26% of Tsc1
2/2
MEFS contained a primary cilium, compared with only 5%
of Tsc1
þ/þ MEFs (P , 0.005, Fig. 2A–D). To conﬁrm that
this enhanced ciliary formation in the Tsc1
2/2 MEFs was
Tsc1-dependent, we examined Tsc1
2/2 MEFs in which either
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was observed: 34% of Tsc1-null MEFs (Tsc1
2/2/vector) con-
tained a primary cilium compared with 12% of Tsc1
2/2
MEFs with re-introduced TSC1 (Tsc1
2/2/TSC1)( P , 0.005,
Fig. 2E and F). To conﬁrm further this unexpected ﬁnding
that loss of Tsc1 enhances ciliary formation, we analyzed
cilia at an earlier time point (24 h after plating) during
logarithmic growth at subconﬂuent levels. Twenty percent of
the Tsc1-null MEFs had a primary cilium, compared with
only 4% of the MEFs re-expressing TSC1 (P , 0.005,
Fig. 2G). These data indicate that loss of Tsc1 enhances
ciliary formation.
In previous work from our laboratory, increased centrosome
numbers were observed in Tsc1-null cells during prolonged
G1/S arrest (63). To determine whether the Tsc1-null and
Tsc2-null cells have an increased number of centrosomes
under the conditions we used to study ciliary formation in
this study, we scored cells for centrosomes after 24 or 48 h
of growth in full serum or 48 h serum starvation. No differ-
ences in centrosome number were detected between
Tsc1
2/2/vector cells (1.1– 4.9% of cells with .2 centro-
somes, depending on the culture conditions) and Tsc1
2/2/
TSC1 cells (1.2–4% of cells with .2 centrosomes, depending
on the culture conditions) (Supplementary Material, Table S1).
Finally, to determine if loss of Tsc1 causes a difference in
cilia length, possibly suggesting defects in normal ciliogen-
esis, we measured the length of Tsc1
2/2/vector and
Tsc1
2/2/TSC1 cilia after 24 or 48 h in 10% fetal bovine
serum (FBS) or 48 h of serum starvation. Interestingly, loss
of Tsc1 lead to a 20–27% increase in cilia length, with an
average cilia length of 1.54 mm for Tsc1
2/2/vector cells and
1.18 mm for Tsc1
2/2/TSC1cells (P , 0.005, Table 1).
Loss of tuberin (Tsc2) enhances ciliary formation
Tuberin and hamartin function as a heterodimer (10,11) and
patients with either TSC1 or TSC2 mutations can develop
renal cysts (1,2). To determine if the enhanced cilia formation
we observed in cells lacking hamartin also occurs after loss of
tuberin, we analyzed ciliary formation in Tsc2
2/2p53
2/2 and
Tsc2
þ/þp53
2/2 MEFs. These cells, which were originally
generated from littermate embryos, are widely used in the
TSC ﬁeld because Tsc2
2/2 MEFs undergo premature senes-
cence and cannot be propagated (66). The Tsc2
2/2p53
2/2
MEFs had a similar phenotype to the Tsc1
2/2 cells: when
ciliary formation was induced by conﬂuency, 70% of the
Tsc2
2/2p53
2/2 MEFs contained a primary cilium compared
with only 12% of the Tsc2
þ/þp53
2/2 cells (Fig. 3A–D,
P , 0.005). When grown for 24 h at subconﬂuent levels,
43% of the Tsc2
2/2p53
2/2 MEFs contained a primary
cilium compared with only 2% of the Tsc2
þ/þp53
2/2 MEFs
(P , 0.005, Fig. 3E). To conﬁrm the speciﬁcity of this
phenotype, we re-expressed GFP-tagged TSC2 in the
Tsc2
2/2p53
2/2 MEFs. Transfected cells were grown for
24 h in 10% FBS, were probed with antibodies to a-acetylated
tubulin (to identify cilia) and g-tubulin (to identify centro-
somes), and GFP-TSC2-positive cells (green) and
GFP-TSC2-negative cells were scored for cilia. Re-expression
of TSC2 reduced the number of ciliated cells from 58 to 12%
(P , 0.005, Supplementary Material, Fig. S2A–D). Similar to
the Tsc1 cells, we found no signiﬁcant difference in centro-
some number between Tsc2
2/2p53
2/2 (1.3–2.4% of cells
with .2 centrosomes, depending on the culture conditions)
and Tsc2
þ/þp53
2/2 cells (1.8–3.5% of cells with .2 centro-
somes) after 24 or 48 h in 10% FBS, or 48 h serum starvation
(Supplementary Material, Table S1).
To determine if loss of Tsc2 is associated with longer cilia,
as was observed in the Tsc1-null cells, we measured the length
of Tsc2
2/2p53
2/2 and Tsc2
þ/þp53
2/2 cilia after 24 or 48 h
in 10% FBS or 48 h of serum starvation. Loss of Tsc2 lead to a
17–22% increase in cilia length, with an average cilia length
of 1.40 mmf o rTsc2
2/2p53
2/2 cells, and 1.13 mm for
Tsc2
þ/þp53
2/2 cells (P , 0.005, Table 1).
Figure 1. Hamartin localizes to the basal body of ciliated human RPE1 and
HK-2 cells. RPE1 and HK-2 cells were serum starved for 48 h to induce
cilia formation. (A) RPE1 cells were ﬁxed and immunostained with
anti-g-tubulin antibody (red) to identify centrosomes, and anti-hamartin anti-
body (TSC1, green). Arrowheads indicate hamartin localization at the centro-
some. (B) RPE1 cells were ﬁxed and immunostained with anti-a-acetylated
tubulin antibody (red) to identify cilia, and anti-hamartin antibody (TSC1,
green). Arrows indicate hamartin at the base of the primary cilia, and arrow-
heads indicate hamartin in the centrosome of cells lacking a primary cilium.
(C) HK-2 cells were ﬁxed and immunostained with anti-a-acetylated tubulin
antibody (red) to identify cilia, and anti-hamartin antibody (TSC1, green).
Arrow indicates hamartin at the base of the primary cilium. Nuclei were
stained with DAPI. All images shown at  100 magniﬁcation.
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is rapamycin-insensitive
The best understood function of TSC1 and TSC2 is to inhibit
the activity of mTORC1 (12–15). To determine if the
enhancement of cilia formation observed in MEFs lacking
TSC proteins is mTORC1-dependent, we treated the cells
with the mTORC1 inhibitor, rapamycin. First we analyzed
the response to rapamycin in cells in which cilia were
induced by conﬂuency. Tsc1
2/2/vector and Tsc1
2/2/TSC1
cells were grown for 48 h in the presence of rapamycin
(20 nmol) or dimethyl sulfoxide (DMSO) control. Rapamycin
did not abrogate the enhanced cilia development phenotype. In
fact, in the Tsc1
2/2/vector MEFs, rapamycin further increased
the number of cells with a primary cilium, from 34% (DMSO)
to 52% (rapamycin) (P , 0.005, Fig. 4A). To verify that the
mTOR pathway remained sensitive to rapamycin after 48 h
growth in 10% FBS, we analyzed phospho-S6 levels by
western blot. Phospho-S6 levels were undetectable in
Tsc1
2/2/vector and Tsc1
2/2/TSC1 cells treated with rapamy-
cin for 48 h (Supplementary Material, Fig. S3A). No differ-
ences in centrosome number were detected in
rapamycin-treated cells (Supplementary Material, Table S1),
but cilia length was signiﬁcantly reduced after rapamycin
treatment in the Tsc1
2/2/vector cells, from 1.58 to 1.30 mm
(P , 0.005, Table 1).
We also tested the effects of rapamycin on
conﬂuency-induced ciliary formation in Tsc2
2/2p53
2/2 and
Tsc2
þ/þp53
2/2 MEFs. As in the Tsc1
2/2 cells, rapamycin
did not abrogate, but instead enhanced, the cilia development
phenotype from 53% (DMSO) to 79% (rapamycin) in
Tsc2
2/2p53
2/2 cells (P , 0.005, Fig. 4B). Similarly, when
cilia were induced in the Tsc2
2/2p53
2/2 and
Tsc2
þ/þp53
2/2 MEFs by serum deprivation (72 h),
Figure 2. Loss of hamartin (Tsc1) enhances ciliary formation. (A) Western immunoblot of Tsc1
2/2 and Tsc1
þ/þ cells showing hamartin levels with b-actin as a
loading control. (B and C) MEFs were maintained at conﬂuency for 48 h to induce cilia formation. Cells were ﬁxed and immunostained with anti-a-acetylated
tubulin antibody (cilia, green) and anti-g-tubulin antibody (centrosomes/basal body, red). Nuclei were stained with DAPI. Arrows indicate the primary cilia.
 100 magniﬁcation. (D) Percentage of cells containing a primary cilium is shown, asterisk indicates P , 0.005. (E) Western immunoblot of Tsc1 re-introduction
cell lines Tsc1
2/2/vector (stably expressing empty vector) and Tsc1
2/2/TSC1 (stably expressing TSC1) showing hamartin levels with b-actin as a loading
control. Phospho-S6 levels are decreased in cells expressing hamartin, as expected. (F) MEFs were maintained at conﬂuency for 48 h to induce cilia formation.
Percentage of cells containing a primary cilium is shown, asterisk indicates P , 0.005. (G) Cells were grown in full serum at subconﬂuent levels for 24 h. Per-
centage of cells containing a primary cilium is shown, asterisk indicates P , 0.005.
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2/2p53
2/2
cells from 66% (DMSO) to 76% ( 0.05, Fig. 4C), and
increased the number of ciliated Tsc2
þ/þp53
2/2 cells from
32% (DMSO) to 43% (P , 0.05). Phospho-S6 levels were
undetectable in both Tsc2
2/2p53
2/2 and Tsc2
þ/þp53
2/2
MEFs treated with rapamycin for 48 or 72 h, conﬁrming the
efﬁcacy of rapamycin in these conditions (Supplementary
Material, Fig. S3B and C). No differences in centrosome
number were detected in rapamycin-treated Tsc2
2/2p53
2/2
or Tsc2
þ/þp53
2/2 cells (Supplementary Material,
Table S1). Unlike the Tsc1 cells, rapamycin treatment had
no effect on cilia length in the Tsc2
2/2p53
2/2 and
Tsc2
þ/þp53
2/2 MEFs, which indicates the possibility of a
role of p53 in ciliary length regulation (Table 1).
Interestingly, when the Tsc2
2/2p53
2/2 MEFS were serum
starved for 72 h to induce cilia, 9% had multiple cilia per cell
(range 2–11 cilia/cell, average 3 cilia/cell), when compared
with ,1% of Tsc2
þ/þp53
2/2 MEFS (P , 0.005, Fig. 4D–
G). This phenotype was rapamycin-sensitive, with 3.7% of
the rapamycin-treated Tsc2
2/2p53
2/2 MEFs having more
than 1 cilia (P , 0.05, Fig. 4D). Taken together, these data
indicate that loss of Tsc2 leads to two ciliary phenotypes:
enhanced ciliary formation, which is rapamycin-insensitive,
and multiple cilia per cell, which is rapamycin-sensitive.
Regulation of ciliary formation by Tsc2
is independent of PC1
PC1 has been shown to bind to TSC2, and it is hypothesized
that cells lacking PC1 have functional inactivation of TSC2
leading to mTOR activation (34–37). Based on this model,
we predicted that cells lacking PC1 would have enhanced
ciliary formation similarly to cells lacking TSC2. To test
this, we utilized MEFs derived from embryos with homo-
zygous disruption of exons 2 and 3 of Pkd1 (67,68). These
Pkd1
2/2 mice have an embryonic lethal phenotype associated
with severely cystic kidneys. First, to determine whether
MEFs normally express PC1 at a level analogous to those of
renal epithelial cells, we used quantitative real-time RT–
PCR to compare Pkd1 mRNA levels in Pkd1
þ/þ and
Pkd1
2/2 MEFs with IMCD3 (inner medullary collecting
duct) cells, which are frequently used to study PC1 function,
and with mPKE (non-immortalized mouse primary kidney epi-
thelial) cells. Pkd1
þ/þ MEFs actually had a higher Pkd1
mRNA level (relative level 100) than IMCD3 and mPKE
cells (relative level 12 and 13, respectively), while the
Pkd1
2/2 MEFs had nearly undetectable Pkd1 levels
(Fig. 5A). Next, to directly compare the Pkd1
2/2 MEFs to
Tsc2
2/2p53
2/2 MEFs with a similar genetic background,
early passage Pkd1
þ/þ and Pkd1
2/2 MEFs were
retrovirally transduced with p53 shRNA to generate immorta-
lized Pkd1
þ/þp53kd(knockdown) and Pkd1
2/2p53kd MEFs
(69). These cells have a .97% decrease in p53 levels as deter-
mined by quantitative real-time RT–PCR (Fig. 5B). Finally, to
determine if Pkd1
2/2p53kd cells have enhanced cilia develop-
ment similar to Tsc2
2/2p53
2/2 MEFs, cells were grown at
subconﬂuent levels in full serum media for 24 h, ﬁxed,
stained and scored for the presence of cilia. As we had
observed in previous experiments, the Tsc2
2/2p53
2/2
MEFs had a markedly elevated number of ciliated cells, com-
pared with the Tsc2
þ/þp53
2/2 MEFs (43 versus 2%, P ,
0.005). In striking contrast to Tsc2
2/2p53
2/2 MEFs, only
8% of the Pkd1
2/2p53kd MEFs had a primary cilium (P ,
0.005, Fig. 5C). These data demonstrate that TSC1 and
TSC2 function primarily independently of PC1 to regulate
primary cilium development in ﬁbroblasts. The fact that
Pkd1
2/2p53kd MEFs had a small, but statistically higher
number of cells with a cilium compared with
Tsc2
þ/þp53
2/2 MEFs, leaves open the possibility that PC1
may have a minor effect on cilia formation.
Table 1. Cilia length in Tsc1 and Tsc2-null and wild-type cells
Cell type Condition Cilia length, mm average (standard deviation) Cilia length, mm median Average cilia length (mm)
a
Tsc1
2/2/vector 24 h FBS subconﬂuent 1.48 (+0.61)
b 1.4 1.54
48 h FBS conﬂuency 1.58 (+0.38)
b 1.6
48 h serum deprivation 1.55 (+0.43)
b 1.5
48 h FBS, rapamycin 1.30 (+0.25)
c 1.3
Tsc1
2/2/TSC1 24 h FBS subconﬂuent 1.08 (+0.22) 1.1 1.18
48 h FBS conﬂuency 1.22 (+0.37) 1.2
48 h serum deprivation 1.24 (+0.27) 1.2
48 h FBS, rapamycin 1.08 (+0.27) 1.1
Tsc2
2/2p53
2/2 24 h FBS subconﬂuent 1.30 (+0.30)
b 1.3 1.40
48 h FBS conﬂuency 1.35 (+0.24)
b 1.3
48 h serum deprivation 1.55 (+0.36)
b 1.4
48 h FBS, rapamycin 1.35 (+0.25) 1.3
Tsc2
þ/þp53
2/2 24 h FBS subconﬂuent 1.08 (+0.25) 1.1 1.13
48 h FBS conﬂuency 1.11 (+0.22) 1.1
48 h serum deprivation 1.21 (+0.23) 1.2
48 h FBS, rapamycin 1.20 (+0.34) 1.1
aAverage cilia length calculated for each cell line from the three culture conditions: 24 h 10% FBS subconﬂuent, 48 h 10% FBS conﬂuency and 48 h
serum deprivation.
bCilia length of Tsc1
2/2/vector compared with Tsc1
2/2/TSC1, and Tsc2
2/2p53
2/2 compared with Tsc2
þ/þp53
2/2, was statistically signiﬁcant (P , 0.005) for
all conditions tested, Wilcoxon two sample test.
cCilia length of rapamycin treated Tsc1
2/2/vector compared with untreated Tsc1
2/2/vector at 48 h 10% FBS was statistically signiﬁcant (P , 0.005), Wilcoxon
two sample test. Rapamycin treatment of the other three cell lines did not cause a signiﬁcant reduction in cilia length at 48 h 10% FBS.
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the mTOR pathway in ﬁbroblasts
The fact that cells lacking PC1 and cells lacking Tsc2 have
different phenotypes related to ciliary formation led us to
examine mTOR activation in the Pkd1-null cells. To our
knowledge, no prior study has addressed whether PC1-null
cells have dysregulation of the mTOR pathway. To
examine the role of Pkd1 in mTOR regulation, we compared
Pkd1
2/2p53kd MEFs to Pkd1
þ/þp53kd and Tsc2
2/2p53
2/2
MEFs. After 24 h of serum deprivation, the Tsc2
2/2p53
2/2
MEFs had high levels of phosphorylated ribosomal protein
S6 (phospho-S6) as expected because of the known role of
TSC2 in inhibiting mTOR. In contrast, both the Pkd1
þ/þ
p53kd and Pkd1
2/2p53kd MEFs had low levels of
phospho-S6 after 24 h of serum deprivation. Fifteen
minutes after serum stimulation, both the Pkd1
þ/þp53kd
and the Pkd1
2/2p53kd MEFs showed marked enhancement
of mTOR activation (Fig. 6A). To conﬁrm that this effect
is related to the loss of Pkd1, and not a consequence of
p53 loss, we compared early passage primary cultures of
Pkd1
2/2 MEFs to the Pkd1
2/2p53kd MEFs and
Tsc2
2/2p53
2/2 MEFs. Both primary and immortalized
Pkd1
2/2 MEFs had low levels of phospho-S6 in serum
deprivation conditions (Fig. 6B). These data demonstrate
that loss of PC1 does not constitutively activate mTOR in
ﬁbroblasts.
ADPKD kidneys contain cysts both with
and without evidence of mTOR activation
Because cells lacking PC1 have low levels of activated mTOR
in serum deprivation conditions, we next re-examined mTOR
activation in ADPKD. Parafﬁn-embedded tissue specimens
from 7 ADPKD patients were stained with anti-phospho-S6
ribosomal protein (Ser 235/236), and 121 individual cysts
were scored using a semi-quantitative scale as reported pre-
viously (70,71). Strong (3þ) to moderate (2þ) phospho-S6
immunoreactivity was evident in 36 cysts (30%) (Table 2).
Importantly, the other 70% had weak (1þ) or negative
phospho-S6 immunoreactivity. Similar staining patterns were
observed using anti-phospho-mTOR (Ser2448), with 35% of
cysts staining strongly or moderately positive (Table 3).
Both positively staining and negatively staining cysts were
identiﬁed in each patient, as illustrated in Figure 7. Cysts
tended to have a homogeneous staining pattern, with the
entire cyst staining either positive or negative. Weakly
Figure 3. Loss of tuberin (Tsc2) enhances ciliary formation. (A) Western immunoblot of Tsc2
2/2p53
2/2 and Tsc2
þ/þp53
2/2 cells showing tuberin levels with
b-actin as a loading control. The upper band appearing in both lanes is a cross-reactive band often observed with this antibody. (B and C) Tsc2
2/2p53
2/2 MEFs
and Tsc2
þ/þp53
2/2 MEFs were maintained at conﬂuency for 48 h to induce cilia formation. Cells were ﬁxed and immunostained with anti-a-acetylated tubulin
antibody (cilia, green) and anti-g-tubulin antibody (centrosomes/basal body, red). Nuclei were stained with DAPI. Arrows indicate the primary cilia.  100 mag-
niﬁcation. (D) Percentage of cells containing a primary cilium is shown, asterisk indicates P , 0.005. (E) Cells were grown in full serum at subconﬂuent levels
for 24 h. Percentage of cells containing a primary cilium is shown, asterisk indicates P , 0.005.
156 Human Molecular Genetics, 2009, Vol. 18, No. 1positive phosphorylation of S6 was seen in the renal epi-
thelium of some normal renal tubules (not shown), as we
have previously observed (70). In some cases, the phospho-S6
and phospho-mTOR-positive cells were larger and more
cuboidal in shape than the negative cells (arrows, Fig. 7).
The fact that only 30% of ADPKD cysts have evidence of
activation of the mTOR/S6K signaling pathway was unex-
pected, for this implies that mutational inactivation of PKD1
is not sufﬁcient to activate mTOR. One possible explanation
for the discordance between these results and the hypothesized
PC1-TSC2-TOR signaling axis (which would predict uniform
activation of mTOR in PKD1 cysts) is that mTOR is initially
uniformly active, but that ﬁbrosis and consequent hypoxia in
end-stage disease inhibit mTOR.
DISCUSSION
The mechanisms through which mutations in the TSC1 or
TSC2 genes contribute to the development of renal cysts are
not well understood. We report here that TSC1 is localized
to the basal body of the primary cilium, and that ﬁbroblasts
lacking either Tsc1 or Tsc2 have a phenotype of enhanced
ciliary formation in three different conditions: logarithmic
growth; conﬂuency-induced ciliary formation and serum
deprivation-induced growth arrest. In addition, cells lacking
Tsc1 or Tsc2 have cilia that are on average 17–27% longer
than wild-type cells, which indicates a defect in normal cilio-
genesis. The pathogenesis of many renal cystic diseases has
been linked with dysfunction of the primary cilium (e.g.
ADPKD, autosomal recessive PKD, nephronophthisis, OFD1
and BBS; 42–44,50,52,53,72). Mutations in some proteins
associated with renal cystic disease result in complete loss
of the primary cilium (e.g. polaris, KIF3A and VHL)
(51,55,57–59), while increases in ciliary length have been
reported in cell culture and kidney tubules from mutations in
the renal cystic disease associated Bbs4 and Nek8 proteins
(60,61). To our knowledge, increased ciliary formation has
not been previously observed in cells carrying mutations for
Figure 4. Regulation of ciliary formation by Tsc1 and Tsc2 is rapamycin-insensitive. (A) Tsc1
2/2/vector and Tsc1
2/2/TSC1 MEFs were grown in the presence
of 10% FBS for 48 h with rapamycin (20 nmol) or DMSO control. Percentage of cells containing a primary cilium is shown, asterisk indicates P , 0.005, P ¼
NS, no signiﬁcant difference. (B) Tsc2
2/2p53
2/2and Tsc2
þ/þp53
2/2 MEFs were grown in the presence of 10% FBS for 48 h with rapamycin (20 nmol) or
DMSO control. Percentage of cells containing a primary cilium is shown, asterisk indicates P , 0.005, P ¼ NS, no signiﬁcant difference. (C and D)
Tsc2
2/2p53
2/2 and Tsc2
þ/þp53
2/2 MEFs were serum starved for 72 h in the presence of rapamycin (20 nmol) or DMSO control. (C) Percentage of cells
containing a primary cilium is shown. (D) Percentage of cells containing more than one primary cilium is shown, asterisk indicates P , 0.005, section sign
indicates P , 0.05, P ¼ NS, no signiﬁcant difference. (E–G) Examples are shown of single Tsc2
2/2p53
2/2 cells containing more than one primary cilium.
MEFs were serum starved for 72 h, ﬁxed and immunostained with anti-a-acetylated tubulin antibody (cilia, green) and anti-g-tubulin antibody (centrosomes/
basal body, red). Nuclei were stained with DAPI. Arrows indicate primary cilia.  100 magniﬁcation.
Human Molecular Genetics, 2009, Vol. 18, No. 1 157genes associated with renal cystic disease. These data, there-
fore, may reveal a novel paradigm in which enhanced ciliary
development is associated with renal cyst pathogenesis.
The best studied function of the TSC1 and TSC2 proteins
is to inhibit the activity of mTORC1 (12–17,23–28). We
found that Tsc1
2/2 and Tsc2
2/2p53
2/2 MEFs treated with
the mTORC1 inhibitor rapamycin actually increased, rather
than reduced cilia numbers, which demonstrates that the
enhanced cilia formation in these cells is mTORC1-
independent. The relative contributions of mTOR-dependent
and mTOR-independent mechanisms to cyst pathogenesis in
TSC are not known. In a Tsc1
þ/2 mouse model, only 53
and 37% of cyst epithelial cells were positive for phospho-
mTOR and phospho-S6 immunostaining, respectively,
compared with .90% of cystadenomas and renal cell carci-
nomas that stained positively for both markers. This suggests
that activation of the mTOR pathway may not be the key
initiating event in cyst development (73). It is known that
treatment with rapamycin reduces the size of renal angiomyo-
lipomas in patients with TSC (74) and reduces the severity of
kidney lesions (cysts and tumors) in rodent models (75–77),
but the impact of rapamycin on cystic disease in humans with
TSC is not yet known. Our unexpected ﬁnding that rapamycin
treatment further enhances cilia formation in the Tsc1 and
Tsc2-null cells may have important implications for treating
renal cystic disease in TSC patients. This may suggest that
the TSC proteins regulate the primary cilium through both
mTORC1-dependent and mTORC1-independent mechan-
isms. These mechanisms may differentially impact ciliary
assembly, elongation and/or maintenance, and in turn these
mechanisms may differentially impact cyst initiation and
cyst progression. The efﬁcacy of rapamycin on renal cystic
disease in patients carrying TSC gene mutations or a con-
tiguous PKD1/TSC2 deletion may therefore differ from the
efﬁcacy of rapamycin on renal cystic disease in patients
carrying PKD1 mutations.
In addition to enhanced ciliary formation, 9% of
Tsc2
2/2p53
2/2 MEFs had multiple primary cilia per cell,
which was partially corrected by treatment with rapamycin.
Therefore, the TSC pathway appears to have both mTOR-
independent and mTOR-dependent roles in ciliary formation.
We have previously observed that Tsc1
2/2 MEFs have extra
centrosomes after a 40 h G1/S arrest (63), and others have
reported that Tsc2
þ/EK pulmonary vascular smooth muscle
cells (SMCs) derived from Eker rats have increased centro-
some number compared with Tsc2
þ/þ SMCs (78). However,
under the conditions used to study ciliary formation in this
study, extra centrosomes were not observed in either the
Tsc1-null or the Tsc2-null cells, which suggests that the
multiple-cilia-per-cell phenotype is not a consequence of mul-
tiple centrosomes (63).
Mutations in either TSC1 or TSC2 alone can lead to poly-
cystic kidney disease, but renal failure is uncommon.
Mutations in PKD1 alone lead to renal failure in 50% of
cases, at an average age of 60 years (29,30). The severe
renal cystic disease observed in infants with contiguous del-
etion of both TSC2 and PKD1 is consistent with a synergistic
functional connection between TSC and ADPKD (2,3,32,79).
It has been previously shown that TSC2 is required for correct
localization of PC1 to the cell membrane, placing TSC2
upstream of PC1 (80). More recently, it has been proposed
that PC1 inhibits the activity of mTOR via a direct interaction
Figure 5. Pkd1
2/2p53kd cells do not have enhanced cilia development. (A) Quantitative real-time RT–PCR analysis of Pkd1 mRNA levels in IMCD3 cells,
non-immortalized mouse primary kidney epithelial (mPKE) cells, Pkd1
þ/þ MEFs and Pkd1
2/2 MEFs. RNA concentration was determined by Nanodrop spec-
trophotometry, and RT–PCR results are normalized to levels of TATA-binding protein. (B) Quantitative real-time RT–PCR analysis of p53 levels of Pkd1
þ/þ
and Pkd1
2/2 MEFs before and after immortalization with p53 shRNA. (C) Cells were grown in full serum at subconﬂuency for 24 h. Percentage of cells contain-
ing a primary cilium is shown, asterisk indicates P , 0.005, section sign indicates P , 0.05.
158 Human Molecular Genetics, 2009, Vol. 18, No. 1with TSC2, placing PC1 upstream of TSC2 (34). We found
that Pkd1
2/2 MEFs do not exhibit enhanced cilia develop-
ment as do the Tsc1
2/2 and Tsc2
2/2p53
2/2 MEFs, indicat-
ing that at least for this particular ciliary phenotype, PC1 is
not functioning upstream of TSC2. PC1 localizes to the
primary cilium and is involved in sensing physiological ﬂuid
ﬂow (38,39,81,82). We speculate, therefore, that TSC2 and
PC1 may cooperatively regulate different aspects of ciliary
development and function, with TSC2 regulating ciliary for-
mation and PC1 sensing physiological ﬂuid ﬂow, thereby
synergistically contributing to renal cyst formation in patients
with contiguous deletion of both genes.
In striking contrast to Tsc2
2/2p53
2/2 MEFs, Pkd1
2/2
MEFs showed no evidence of mTOR activation under serum
deprivation conditions. This is surprising considering the inter-
action of PC1 (overexpressed C-terminal cytoplasmic tail)
with TSC2 that was hypothesized to underlie the activation
of mTOR observed in renal cystic epithelial cells from patients
with ADPKD (34–37). One possible explanation is that the
Pkd1 disruption in the Pkd1
2/2 MEFs used for our studies,
which occurs by homologous recombination of a
b-galactosidase/neomycin cassette in place of exons 2 and 3
of Pkd1, leaves a partially functional region of PC1 intact
(67,68). A second potential explanation for the discordance
between our data and the previously proposed models for
the relationship between PC1 and TSC2 is that there are
differences in the regulation of mTOR activity by PC1
between ﬁbroblasts and epithelial cells. This could be
clinically important since ADPKD patients develop non-
epithelial manifestations, including mitral valve prolapse and
aortic and intracranial aneurysms (29–31,83). However, we
note that MEFs have been used by other groups to study the
roles of VHL, PDGFRaa, KIF3A and other proteins in
ciliary formation and function, and in general, results have
been concordant between ﬁbroblasts and epithelial cells
when both cell types were analyzed (55,84–87).
Multiple signaling cascades converge on TSC2, leading toits
phosphorylation and inactivation (88–92). Interestingly, loss
of Pkd1 has been shown to result in activation of Akt and
MAPK (93,94), and Akt and MAPK activation can lead to
mTOR activation via direct phosphorylation and inactivation
of TSC2 (88–91), yet mTOR was not activated in our
Pkd1
2/2 MEFs. While loss of PC1 does not appear sufﬁcient
to activate mTORC1, it may act cooperatively with other path-
ways to potentiate cyst pathogenesis (Fig. 8). Consistent with
this, we ﬁnd that 30–35% of ADPKD cysts have strong to
moderate immunohistochemical evidence of mTOR pathway
activation, while 65–70% do not, potentially reﬂecting acti-
vation of other pathways upstream of TSC2 and mTOR.
Elucidating the mechanism through which mTOR is regu-
lated in ADPKD has critical clinical implications, since at
least four clinical trials of mTOR inhibitors are ongoing for
patients with PKD to determine if these drugs can slow cyst
progression, reduce cyst volume and improve renal function
(95). Our data suggest that mutational activation of PKD1 is
not sufﬁcient to activate mTOR and that other events which
may be mediated by TSC2 are required to activate mTOR in
ADPKD cysts, thereby leading to cyst progression. These
other events may distinguish cyst initiation from cyst pro-
gression and could reveal novel therapeutic options for
patients with ADPKD, which affects 12.5 million people
world-wide, accounts for 8–10% of all patients on dialysis,
and leads to $2 billion per year in health care costs in the USA.
MATERIALS AND METHODS
Cell culture
Human retinal pigmented epithelial cells (hTERT-RPE1) were
obtained from the American Type Culture Collection. RPE1
cells were maintained in 1:1 DMEM:F12 media containing
10% FBS and 10 mg/ml Hygromycin B. Immortalized human
kidney proximal tubule epithelial (HK-2) cells (American
Type Culture Collection) were maintained in DMEM with
10% FBS and ITS liquid media supplement (Sigma).
Tsc1
þ/þ, Tsc1
2/2, Tsc2
þ/þp53
2/2, and Tsc2
2/2p53
2/2
MEFs have been previously described (6,66,96) and were
Figure 6. Loss of Pkd1 does not constitutively activate the mTOR pathway.
MEFs were serum deprived overnight, then stimulated for 15 min in the
presence of 20% FBS. Immunoblots were probed with phospho-S6 to deter-
mine the level of mTOR activation. b-actin was used as a loading control.
(A) Western immunoblot of Tsc2
2/2p53
2/2, Pkd1
þ/þp53kd MEFs and
Pkd1
2/2p53kd MEFs. (B) Western immunoblot of Tsc2
2/2p53
2/2,
Pkd1
2/2 primary MEFs and Pkd1
2/2p53kd MEFs. Similar results were
seen in four independent experiments.
Table 2. Phospho-S6 immunoreactivity of ADPKD renal cysts
Patient number Number of cysts scored
2 1þ 2þ 3þ
305 6 7 3 1
427 2 4 1 0
433 11 10 5 3
513 6 1 3 1
550 3 3 1 0
555 16 6 2 6
611 8 2 7 3
Total number (%) 52 (43) 33 (27) 22 (18) 14 (12)
Anti-phospho-S6 ribosomal protein (Ser 235/236) staining of cyst lining
epithelial cells was scored using a semi-quantitative scale of negative (2),
weakly positive (1þ), moderately positive (2þ) or strongly positive (3þ),
as reported previously (70,71).
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acids. TSC1-null re-introduction MEFs have been previously
described (63). Non-immortalized mPKE were derived from
a wild-type C57BL/6 mouse and were maintained in low
calcium DMEM/F12 media (Invitrogen #90-5212EF) with 5%
horse serum. The Pkd1
2/2 MEFs were isolated from
Pkd1
2/2 mice that have homologous recombination of a
b-galactosidase/neomycin cassette that disrupts exons 2 and 3
(67,68). Wild-type and Pkd1
2/2 MEFs were immortalized by
transduction of a retroviral vector containing shRNA targeting
p53 (69). For immortalization, 5   10
6 293T Phoenix packa-
ging cells were transfected with 7 mg shRNA plasmid (p53E
or empty vector) with 5 mg helper plasmid containing retroviral
gag/pol genes using Fugene 6 (Roche). After 48 h, the target
MEFs were infected twice daily for 2 days with the media
from the Phoenix cells ﬁltered through a 0.45 mm ﬁlter. MEF
media was changed twice daily for the next 2 days, and then
media was supplemented with 1.5 mg puromycin to select for
infected cells for the next 72 h. All cells losing p53 are immor-
talized, and puromycin selection is no longer necessary.
Assays of ciliary formation
To study cilia three different conditions were used, as speci-
ﬁed in the text: cells were serum starved for 48–72 h to
induce cilia formation, cells were cultured with cell-to-cell
contact inhibition in the presence of 10% FBS for 48 h to
induce ciliary formation, or cells were grown logarithmically
in the presence of 10% FBS at subconﬂuency for 24 h. Each
result was conﬁrmed in at least three independent experiments.
Due to variation in seeding density, absolute numbers of
primary cilia differed between experiments by 10–30%, but
the fold increase caused by loss of Tsc1 or Tsc2 remained con-
sistent. Rapamycin (20 nmol) and DMSO were added to the
media for the full 48 or 72 h of ciliary induction, as indicated.
For GFP-TSC2 re-expression in Tsc2
2/2p53
2/2 MEFs, cells
were plated on coverslips and transfected with GFP-TSC2
plasmid DNA using Fugene 6 (Roche). After 24 h growth in
10% FBS, cells were ﬁxed and stained. For each culture con-
dition, at least 150 cells were scored for the presence of a
primary cilium, and at least 200 cells scored for the number
of centrosomes by an observer blinded to the experimental
conditions. For cilia measurements, at least 50 randomly
chosen cilia were measured (from base to tip) per cell line
for each culture condition at 1000  magniﬁcation using a
Nikon Coolsnap ES camera and Image-Pro Express 2000 soft-
ware (Media Cybernetics, Inc.).
Immunoﬂuorescence
RPE1, HK-2 or MEF cells were grown in conditions to stimu-
late cilia formation and then ﬁxed for 10 min in 100% metha-
nol on ice. Cells were washed three times in PBS, incubated
for 5 min in 0.2% Triton-X in PBS, and then washed three
times in Triton-X PBS. Primary antibodies [a-acetylated
tubulin (Sigma) 1:1000, g-tubulin (Abcam) 1:1000, Hamartin
(Zymed) 1:100] were added for 1 h at room temperature, and
then cells were washed three times with Triton-PBS. Second-
ary antibody [alexa ﬂuor 488 or 594 (Molecular Probes)
1:1000] were added for 1 h at room temperature, then cells
were washed 3  2 min with Triton-PBS. Cells were incubated
with DAPI for 1 min at room temperature, washed in PBS and
mounted using anti-fading gel mount (Biomeda). Cells were
viewed by Nikon Coolsnap ES and pictures taken with
Image-Pro Express 2000 software (Media Cybernetics).
Western blotting
Cells were washed once in PBS on ice, then lysed in PTY
buffer (50 mM HEPES, pH 7.5, 50 mM NaCl, 50 mM NaF,
Figure 7. ADPKD kidneys contain cysts both with and without evidence of
mTOR activation. Cysts from seven ADPKD patients were stained using
phospho-S6 (Ser 235/236) and phospho-mTOR (Ser 2448) antibodies. Thirty
percent had moderate or strong immunoreactivity with anti-phospho-S6, and
35% had moderate or strong immunoreactivity with anti-phospho-mTOR.
Representative examples of positive and negative cysts are shown.
Phospho-mTOR and phospho-S6-positive cysts tended to have larger cells
with a more cuboidal shape (black arrow). The negative cells tended to
have a ﬂattened shape. Occasionally, the phospho-S6 and
phospho-mTOR-positive cysts had papillary projections (white arrows,
patient 611).  40 magniﬁcation.
Figure 8. Working model. TSC1 and TSC2 regulate cilia formation in a
TORC1/rapamycin-independent manner. Multiple signaling cascades, includ-
ing MAPK, Akt and Rsk1, converge on TSC2, leading to its phosphorylation
and inactivation and contributing to mTOR activation. Loss of PC1 does not
appear sufﬁcient to activate TOR or impact ciliary formation via TSC2.
However, PC1 may cooperate with the multiple signaling cascades to initiate
or enhance cystogenesis.
Table 3. Phospho-mTOR immunoreactivity of ADPKD renal cysts
Patient number Number of cysts scored
2 1þ 2þ 3þ
305 20 6 5 10
427 23 4 6 7
Total number (%) 43 (53) 10 (12) 11 (14) 17 (21)
Anti-phospho-mTOR (Ser 2448) staining of cyst lining epithelial cells was
scored using a semi-quantitative scale of negative (2), weakly positive
(1þ), moderately positive (2þ) or strongly positive (3þ), as reported
previously (70,71).
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protease inhibitors), or in RIPA buffer (150 mM NaCl,
50 mM Tris, pH 8.0, 1% Triton X, 1% deoxycholic acid,
0.1% SDS, 2 mM PMSF, Sigma protease inhibitors). Proteins
were run on 4–20% SDS–PAGE, then transferred to
Immobilon-P (Millipore) membrane. Western blots were
probed with antibodies to b-actin (Sigma, A2228), hamartin
[TSC1] (Zymed, 37–0400), phospho-S6 ribosomal protein
[Ser235/236] (Cell Signaling, 2211) and tuberin [TSC2]
(Santa Cruz, sc-893).
Immunohistochemistry
ADPKD specimens were obtained at the time of nephrectomy
through the Polycystic Kidney Research Foundation.
Formalin-ﬁxed, parafﬁn-embedded ADPKD kidney sections
were deparafﬁnized and rehydrated according to standard pro-
cedures. Slides were boiled in 10 mM citrate buffer, pH 6.0 for
10 min in the microwave. After cooling, slides were quenched
with 3% hydrogen peroxide in methanol for 30 min at room
temperature. For staining procedures, the Histo-stain Plus kit
(Zymed) was used according to manufacturer’s instructions.
Phospho-S6 [(Ser235/236) Cell Signaling] and phospho-
mTOR [(Ser2448) #2967] antibodies were used in a 1:50
dilution in PBS. Cysts were scored for phospho-S6 and
phospho-mTOR staining using a scale of negative (2),
weakly positive (1þ), moderately positive (2þ) or strongly
positive (3þ).
Reverse transcription polymerase chain reaction
Total mRNA was isolated from IMCD3, mPKE and MEF cell
lines using the RNeasyTM Mini-kit (Qiagen). RNA concen-
tration was determined using NanoDropTM Spectrophotometer
(Thermo Scientiﬁc). For each sample, two reverse transcrip-
tion reactions were performed with 100 and 20 ng of input
RNA. 50-Nuclease assays using TaqMan chemistry were run
on a 7900 HT sequence detection system (Applied Biosys-
tems). Ct (cycle threshold) values were converted to quantities
(in arbitrary units) using standard curve (ﬁve points, 5-fold
dilutions) established with a calibrator sample. Quantitative
real-time RT–PCR results were normalized to TATA-binding
protein mRNA levels. For each sample, the two values of
relative quantity (from two PCR assays) were averaged.
Statistical analysis
A two-tailed Fisher’s exact test was used for all statistical
analysis of cilia number per cell and centrosome number per
cell. For comparisons of cilia length, a Wilcoxon two
sample test was performed. Signiﬁcance was achieved at
P   0.05.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG Online.
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